Delinking the cost of R&D from the final prices of medicines and making governments the funders and planners of drug development would be rife with problems.
June 6, 2017
Speeding Cures for Patients: How Congress Can Update the Prescription Drug User Fee Act to Spur Biopharmaceutical Innovation
For more than two decades, the Prescription Drug User Fee Act (PDUFA) has underpinned America’s leadership in biopharmaceutical innovation. Join ITIF for a discussion with policy experts, industry leaders, and patient advocates to discuss why a timely reauthorization of PDUFA is critical to the future of medical innovation.
May 30, 2017
Fact of the Week: Pharmaceutical Innovation Accounted for 73 Percent of the Increase in Life Expectancy in 30 Developing and Developed Countries From 2000 to 2009
Pharmaceutical innovation accounted for 73 percent of the increase in life expectancy (approximately 1.73 years) in 30 developing and developed countries from 2000 to 2009, writes John Wu in Innovation Files.
March 21, 2017
Bipartisan collaboration on the Hill has proven scant in the opening weeks of the Trump era, but the opportunity to reauthorize the Prescription Drug User Fee Act provides a welcome occasion for bipartisan comity while extending legislation that has played a foundational role in underpinning U.S. life-sciences leadership and helping bring safe, innovative cures to patients faster, writes Stephen Ezell in Innovation Files.
February 27, 2017
PDUFA enables a safe, timely, and efficient process of drug evaluation while applying best practices in regulatory science that support America’s global leadership in biomedical innovation.
November 3, 2016
How the Trans-Pacific Partnership Agreement Will Strengthen Singapore’s Innovation Economy (Like America’s)
As Singapore continues its efforts to transform a small island nation into a global innovation hub, the innovation-enabling trade regime the Trans-Pacific Partnership fosters will benefit all industries but especially advanced technology ones, in areas such as life sciences and information technology, on which Singapore’s economy (like America’s) increasingly thrives, writes John Wu in Innovation Files.
November 2, 2016
Fact of the Week: When a Breakthrough Drug Receives an Additional Year of Market Exclusivity, 20% More Drugs are Approved in the Same Class.
Every additional year of market exclusivity given to a breakthrough compound increases the number of subsequent drugs approved in that class by between 18 and 25 percent—20 percent on average, writes John Wu in Innovation Files.
July 14, 2016
The UN high-level access to medicines panel must consider the complete range of factors impacting access to medicines, writes Stephen Ezell in Innovation Files.
July 12, 2016
In Innovation Files, Stephen Ezell provides an overview of localization barriers to trade in the life sciences sector recently enacted by countries around the world.
July 11, 2016
Spurring biopharmaceutical innovation to understand and cure brain diseases and disorders could improve health outcomes for more than 50 million Americans while increasing GDP by up to $1.5 trillion or more.
July 11, 2016
Join ITIF for the release of a new report examining the potential economic gains the United States could reap from biopharma innovation that enables improved diagnosis, treatment, cures, and even prevention of mental and neurological health conditions.